Business Description
Bicara Therapeutics Inc
NAICS : 541715
SIC : 2833
ISIN : US0554771032
Total Employee Number:
103Description
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 374.57 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -5.2 | |||||
3-Year EPS without NRI Growth Rate | -0.9 | |||||
3-Year FCF Growth Rate | 2.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -10.75 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 96.01 | |||||
9-Day RSI | 86.84 | |||||
14-Day RSI | 78.04 | |||||
3-1 Month Momentum % | 16.17 | |||||
6-1 Month Momentum % | 30.83 | |||||
12-1 Month Momentum % | 149.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.85 | |||||
Quick Ratio | 13.85 | |||||
Cash Ratio | 13.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -9.23 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -35.55 | |||||
ROA % | -33.6 | |||||
ROIC % | -480.13 | |||||
3-Year ROIIC % | -966.47 | |||||
ROC (Joel Greenblatt) % | -9722.82 | |||||
ROCE % | -39.29 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.54 | |||||
Price-to-Tangible-Book | 3.54 | |||||
EV-to-EBIT | -7.4 | |||||
EV-to-Forward-EBIT | -0.32 | |||||
EV-to-EBITDA | -7.4 | |||||
EV-to-FCF | -11.07 | |||||
| Price-to-Net-Current-Asset-Value | 3.61 | |||||
| Price-to-Net-Cash | 3.65 | |||||
Earnings Yield (Greenblatt) % | -13.51 | |||||
FCF Yield % | -6.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCAX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bicara Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.78 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 39.66 | ||
| 14-Day RSI | 78.04 | ||
| 14-Day ATR ($) | 1.328688 | ||
| 20-Day SMA ($) | 22.215 | ||
| 12-1 Month Momentum % | 149.49 | ||
| 52-Week Range ($) | 8.575 - 28 | ||
| Shares Outstanding (Mil) | 65.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bicara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bicara Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 44 days | ||
| General meeting for 2026 | 2026-06-09 09:00 | 20.10 (-2.14%) | ||
| Guidance call for 2026 | 2026-05-22 08:30 | 20.84 (-0.76%) | ||
| First quarter earnings conference call for 2026 | 2026-05-11 08:30 | 22.58 (-2.12%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 22.58 (-2.12%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 08:30 | 18.37 (-1.50%) | ||
| Annual report for 2025 | 2026-03-30 | 18.37 (-1.50%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 18.37 (-1.50%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-10 11:30 | 19.70 (+7.83%) |
Show
Entries
Bicara Therapeutics Inc Frequently Asked Questions
What is Bicara Therapeutics Inc(BCAX)'s stock price today?
The current price of BCAX is $27.79. The 52 week high of BCAX is $28.00 and 52 week low is $8.57.
When is next earnings date of Bicara Therapeutics Inc(BCAX)?
The next earnings date of Bicara Therapeutics Inc(BCAX) is 2026-08-12 Est..
Does Bicara Therapeutics Inc(BCAX) pay dividends? If so, how much?
Bicara Therapeutics Inc(BCAX) does not pay dividend.
Guru Commentaries on NAS:BCAX
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology | 2025-10-27 |
Articles on Bicara Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers